Adage Capital Partners’s NextCure NXTC Stock Holding History

Adage Capital Partners’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,500	Closed	-$1.5M	–	1049
2021 Q1	$1.5M	Buy	+12,500	New	+$1.81M	﹤0.01%	865

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners's NXTC Position: Q2 2021 in Review

Adage Capital Partners sold out of NextCure (NXTC) in Q2 2021, closing a stake of 12,500 shares — an estimated $1.5M sold.

Adage Capital Partners first reported a position in NXTC in Q1 2021 and held it in 1 quarter. The position peaked at $1.5M in Q1 2021. 78 funds tracked by Wall St. Rank hold NXTC as of Q2 2021.

Adage Capital Partners reported no remaining NextCure position as of Q2 2021 after selling out during the quarter.
Adage Capital Partners sold 12,500 NextCure shares in Q2 2021, an estimated $1.5M.
Adage Capital Partners first reported a position in NextCure in Q1 2021 and held it in 1 quarter.
Adage Capital Partners's NextCure position peaked at $1.5M in Q1 2021.
78 funds tracked by Wall St. Rank held NextCure as of Q2 2021.

Based on Adage Capital Partners's 13F filing for Q2 2021, filed 16 Aug 2021.